Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precigen, Inc. on September 15, 2022. The report discloses a material change in the Company's executive leadership structure effective October 1, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Executive Appointment: The Board of Directors appointed Rutul R. Shah as Chief Operating Officer (COO), effective October 1, 2022.
- Previous Role: Mr. Shah previously served as Vice President, Head of Operations and Portfolio since February 16, 2020.
- Compensation Adjustment: In connection with the appointment, Mr. Shah's annual base salary was increased from $300,000 to $410,000.
- Other Compensation: No other changes were made to his compensation arrangements; he remains eligible for annual performance bonuses and long-term equity incentive awards.
Outlook, Risks, and Management Commentary
The filing highlights Mr. Shah's broad leadership experience in alliance management, portfolio management, and operations, including a decade of prior experience in scientific positions at companies such as Zyngenia, Teva Biopharmaceuticals USA, CoGenesys, and Human Genome Sciences. The filing states there are no undisclosed arrangements regarding his selection and no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the effective date of the COO appointment (October 1, 2022).
- Confirm the new annual base salary of $410,000 for the COO.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.